Ophthalmology
Conjunctivitis
39
Pipeline Programs↗
1
Active Trials↗
15
Companies Involved↗
Conjunctivitis is a moderately active landscape with 39 programs across 15 companies. The most active players are BioTech Tools S.A., Cytos Biotechnology AG, Blueprint Medicines. 9 therapies are approved with 15 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 14
Phase 211
Phase 315
Analysis
Trial Status
58
clinical trials
Completed51 · 88%
Unknown status5 · 9%
Enrolling by invitation1 · 2%
Withdrawn1 · 2%
Clinical Trials
Trial Activity
58 trials
Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis
Enrolling by invitation·—·Phase 3·NCT04275232·1 enrolled
Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
Completed·—·Phase 3·NCT00409409·278 enrolled
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
Completed·—·Phase 3·NCT01731249·574 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)